CGP 33304 is a dual leukotriene receptor antagonist and phospholipase A2 inhibitor. It prevents hypoxia secondary to bronchial constriction induced by leukotriene in a shocking state.
GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with an SC50 of 344 nM. GP33-41 Epitope is a strong agonist of CD8 T cells.
CP-339818 is of great value in immune system studies, where the loss of Kv1.4 makes it functionally selective to Kv1.3, and it has shown inhibition of T cell activation.
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].
Detorubicin is a semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.
LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is a sequence of lymphocytic choriomeningitis virus restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes. This is the H-2Db restricted epitope derived from the lymphocytic.
PF-00337210 is an orally available ATP-competitive inhibitor of the vascular endothelial growth factor receptor type 2 (VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, the VEGFR2 tyrosine kinase inhibitor PF-00337210 selectively binds to VEGFR2 and prevents its phosphorylation which may result in an inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and may eventually cause tumor cell death. VEGFR2, a receptor tyrosine kinase, is frequently overexpressed by a variety of tumor types.
Detorubicin Free Base is a semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.